Hansa Biopharma: Imlifidase continues to deliver improved sales in early 2024

Research Note

2024-04-02

14:00

Hansa’s preliminary Q1 result suggests that Idefirix records European product sales of SEK 48 (43m in Q4) in Q1. In Q1, Hansa received support from countries like the UK, France, Germany, and Belgium. This is the second consecutive quarter with improved sales compared with the earlier rolling 12m level.

JU

Johan Unnerus

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.